Testing tumor care planning for metastatic kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies a way to plan and manage care for people with metastatic renal cell carcinoma (kidney cancer that has spread). It may help doctors coordinate treatment more effectively to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must live in Denmark.
- You must have metastatic renal cell carcinoma (kidney cancer that has spread).
- You must already be receiving medical treatment for your cancer.
- You must be able to provide written informed consent.
- You should have no major reason you cannot join based on the study’s consent requirement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
Hear when a new Drug Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.